\
&
Contact us
Published on | 9 months ago
Programmes Digital, Industry & Space Climate, Energy, MobilityThe Clean Aviation Joint Undertaking is the European Union’s leading research and innovation programme for transforming aviation towards a sustainable and climate-neutral future. It is a European public-private partnership.
Clean Aviation is launching its Third Call for Proposals, calling for innovators and stakeholders across the aviation sector to contribute with disruptive projects to accelerate the decarbonisation of aviation.
With up to €380 million in EU funding, corresponding to a total research effort of €950* million including the additional private investments that will be triggered under the call—this Third Call seeks proposals to integrate and demonstrate the most promising technologies on the aircraft concept models identified in its Strategic Research & Innovation Agenda (SRIA).
* With inclusion of in-kind contribution from entities participating in projects.
The Calls are all backed up by EU funding and focus on:
A major new feature in this call is the Fast Track Activities (FTAs) initiative designed to:
Clean Aviation will be defining its 4th Call for proposal in close cooperation with its public and private members in the course of 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.